| Open Document File Size: 627,94 KBShare Result on Facebook
City Philadelphia / Dublin / Cambridge / Houston / / Company 2Astex Pharmaceuticals Inc. / Johnson and Johnson / Pharmaceuticals Inc. / Astex Pharmaceuticals / / Country United Kingdom / / Currency pence / / Event FDA Phase / / Facility Temple University / University Hospital / The University of Texas MD Anderson Cancer Center / MD1 Institute / / MedicalCondition Leukemia / / MedicalTreatment chemotherapy / / Organization 5Temple University Hospital / MD1 Institute for Cancer and Molecular Biology / Temple University / Philadelphia / University of Texas / / Person Yong Hao / Jean Pierre Issa / John F Lyons / Pathogenic Characteristics / Patricia Kropf / Mohammad Azab / / Position Representative / / Product SGI-110 / / ProvinceOrState Texas / Pennsylvania / California / / PublishedMedium Molecular Biology / / Technology Gene expression / chemotherapy / pharmacodynamics / /
SocialTag |
1442 Determinants of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study Woonbok Chung, PhD1, Pietro Taverna, PhD2, John F L